New therapy against breast cancer: mRNA cancer vaccines

Zhengwei Jin

doi:10.54097/ntxary24

Authors

Zhengwei Jin

DOI:

https://doi.org/10.54097/ntxary24

Keywords:

Breast cancer, mRNA, Vaccines.

Abstract

Breast cancer is the common diagnosed cancer around the world with high rate of incidence and mortality. Nowadays, although endocrine therapy, and anti-HER2 targeted therapy got a advance in chemotherapy in the past decades, but our studies face the challenge about the relapse and metastasis of breast cancer. Human beings are in need of innovative treatment strategies to change this situation. Immunotherapy has become the mainstream cancer treatment strategy in recent years. mRNA tumor vaccine has gradually occupied the main position in breast cancer treatment with its special advantages of low toxicity, fast manufacturing and safety, high efficiency, and mRNA vaccine has great advantages over current vaccines. This article mainly reviews the progress of mRNA vaccine in breast cancer, and summarizes the possible challenges.

Downloads

Download data is not yet available.

References

Siegel RL, Miller KD, et al. Cancer Statistics, 2017. CA Cancer J Clin. 2017, 67:7–30.

Majeed W, Aslam B, et al. Breast cancer: major risk factors and recent developments in treatment. APJCP. 2014, 15: 3353-3358.

Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol. 2022, 13: 828386.

Pastor F, Berraondo P, et al. AnRNA Toolbox for Cancer Immunotherapy. Nat Rev Drug Discov. 2018, 17(10):751–67.

Duan LJ, Wang Q, et al. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol. 2022, 13:923647.

Miao L, Zhang Y, et al. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021, 20(1):41.

Zeng C, Zhang C, et al. Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol 2020, 2: 1–40.

Bauer K.R,Brown M, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007, 109:1721-1728

Sun YS, Zhao Z, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017, 13(11):1387-1397.

Qian BZ, and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141: 39-51.

Sgroi DC. Preinvasive breast cancer. Annu Rev Pathol. 2010, 5:193–221.

Dine J, Deng CX. Mouse models of BRCA1 and their application to breast cancer research. Cancer Metastasis Rev. 2013, 32:25–37.

Bane AL, Beck JC et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007, 31:121–128.

Majeed W, Aslam B et al. Breast cancer: major risk factors and recent developments in treatment. APJCP. 2014, 15: 3353-3358.

Al-Awadhi A, Lee Murray J, et al. Developing Anti-HER2 Vaccines: Breast Cancer Experience. Int J Cancer 2018, 143:2126–32.